搜索
NewAmsterdam Pharma Company NV
NAMS添加自选
33.890USD
+0.020+0.06%
收盘 06/30, 16:00（美东）报价延迟15分钟
3.96B总市值
亏损市盈率 TTM
关键数据
34.590今开
34.725最高
1.08M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.92%换手率
33.870昨收
33.575最低
27.88M成交额
亏损市盈率静
5.94市净率
0.00%股息率 TTM
-27.43%ROA
42.00052周最高
0.79量比
-241.60M净利润
116.64M总股本
-1.7787每股收益TTM
0.16Beta
-29.49%ROE
14.06052周最低
3.40%振幅
100.00%毛利率
3.96B总市值
1.89回报/风险
3.46%风险率
TradingKey NewAmsterdam Pharma Company NV股票评分
单位: USD 更新时间: 2026-06-30操作建议
NewAmsterdam Pharma Company NV当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名20/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价51.50。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
NewAmsterdam Pharma Company NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
NewAmsterdam Pharma Company NV亮点
亮点风险
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
业绩高增长
公司营业收入稳步增长，连续3年增长59.71%
业绩增长期
公司处于发展阶段，最新年度总收入22.50M美元
利润高增长
公司净利润处于行业前列，最新年度总收入22.50M美元
估值低估
公司最新PE估值-19.05，处于3年历史低位
机构加仓
最新机构持股128.70M股，环比增加1.86%
分析师目标
根据
16
位分析师
买入
评级
51.500
目标均价
+52.05%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NewAmsterdam Pharma Company NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NewAmsterdam Pharma Company NV简介
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
公司代码NAMS
公司NewAmsterdam Pharma Company NV
CEODavidson (Michael Harvey)
网址https://ir.newamsterdampharma.com/
相关品种
热门品种
常见问题
NewAmsterdam Pharma Company NV(NAMS)的当前股价是多少？
NewAmsterdam Pharma Company NV(NAMS)的当前股价是 33.89。
NewAmsterdam Pharma Company NV的股票代码是什么？
NewAmsterdam Pharma Company NV的股票代码是NAMS。
NewAmsterdam Pharma Company NV股票的52周最高点是多少？
NewAmsterdam Pharma Company NV股票的52周最高点是42.00。
NewAmsterdam Pharma Company NV股票的52周最低点是多少？
NewAmsterdam Pharma Company NV股票的52周最低点是14.06。
NewAmsterdam Pharma Company NV的市值是多少？
NewAmsterdam Pharma Company NV的市值是3.95B。
现在NewAmsterdam Pharma Company NV(NAMS)的股票是买入、持有还是卖出？
根据分析师评级，NewAmsterdam Pharma Company NV(NAMS)的总体评级为买入，目标价格为51.50。
NewAmsterdam Pharma Company NV(NAMS)股票的每股收益（EPS TTM）是多少
NewAmsterdam Pharma Company NV(NAMS)股票的每股收益（EPS TTM）是-1.72。
